Cue Health

A new study published in Microbiology Spectrum put Cue Health’s (NASDAQ: HLTH) COVID-19 test head-to-head with lab-based PCR tests, which have become the gold standard in diagnostic accuracy for the virus — and found that, when used at the point-of-care, the Cue COVID-19 Test...

The healthcare technology company Cue Health Inc. (NASDAQ: HLTH) has become the first company to get De Novo authorization from the U.S. Food and Drug Administration (FDA) for an over-the-counter COVID-19 test — as well as being the first FDA De Novo authorization for any over-the-counter...

Last month, the Food and Drug Administration (FDA) granted a landmark De Novo authorization for Cue Health’s (NASDAQ: HLTH) at-home COVID-19 test that delivers lab-quality results within 20 minutes. The move makes Cue Health the first company to receive De Novo authorization for an at-home...

Last month, the Food and Drug Administration (FDA) granted a landmark De Novo authorization for Cue Health’s (NASDAQ: HLTH) at-home COVID-19 test that delivers lab-quality results within 20 minutes. The move makes Cue Health the first company to receive De Novo authorization for an at-home...